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Alexander disease (AxD) is a rare, autosomal dominant neurological disorder. Three
clinical subtypes are distinguished based on age at onset: infantile (0–2 years), juvenile
(2–13 years), and adult (>13 years). The three forms differ in symptoms and prognosis.
Rapid neurological decline with a fatal course characterizes the early-onset forms, while
symptoms are milder and survival is longer in the adult forms. Currently, the sole known
cause of AxD is mutations in the GFAP gene, which encodes a type III intermediate
filament protein that is predominantly expressed in astrocytes. A wide spectrum of GFAP
mutations comprising point mutations, small insertions, and deletions is associated with
the disease. The genotype-phenotype correlation remains unclear. The considerable
heterogeneity in severity of disease among individuals carrying identical mutations
suggests that other genetic or environmental factors probably modify age at onset or
progression of AxD. Describing new cases is therefore important for establishing reliable
genotype-phenotype correlations and revealing environmental factors able to modify age
at onset or progression of AxD. We report the case of a 54-year-old Caucasian woman,
previously diagnosed with ovarian cancer and treated with surgery and chemotherapy,
who developed dysarthria, ataxia, and spastic tetraparesis involving mainly the left side.
Cerebral and spinal magnetic resonance imaging (MRI) revealed a peculiar tadpole-like
atrophy of the brainstem. Genetic analysis of the GFAP gene detected a heterozygous
mutation in exon 1 (c.219G>C), resulting in an amino acid exchange from methionine
to isoleucine at codon 73 (p.M73I). The expression of this mutant in vitro affected the
formation of the intermediate filament network. Thus, we have identified a new GFAP
mutation in a patient with an adult form of AxD.
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BACKGROUND
Alexander disease (AxD) is an autosomal dominant neurological disorder (OMIM #203450)
caused by mutations in the glial fibrillary acidic protein (GFAP) gene located on chromosome
17q21.31. AxD is a leukodystrophy characterized by the progressive accumulation in astrocytes
of GFAP aggregates, called Rosenthal fibers, which are spread over the subpial, perivascular,
and subependymal regions of the cortex and white matter. These inclusions impair cytoskeleton
formation and astrocyte survival and functioning, ultimately resulting in demyelination (1).
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AxD is extremely rare. According to the only population-
based study completed to date, the estimated 5-year prevalence
is 1 in 2.7 million (1, 2). Three clinical subtypes are distinguished
based on age at onset: infantile (0–2 years), juvenile (2–13 years),
and adult (>13 years). The early-onset forms are characterized
by progressive neurological decline, with developmental delay,
pyramidal sign, seizure, ataxia, and a fatal course; the median
survival is 14 years (3). The adult form is characterized by normal
cognition, swallowing difficulties, dysarthria, nystagmus, palatal
myoclonus, pyramidal dysfunction, and cerebellar ataxia; the
median survival is 25 years. The symptoms reflect the typical,
marked atrophy and hyperintensity signal in the lower brainstem,
the upper cervical cord, the dentate nucleus, and the middle
cerebral peduncles frequently observed on magnetic resonance
imaging (MRI) in patients with adult-onset AxD (4).
Awide spectrummutation in theGFAP gene is associated with
the disease (https://www2.waisman.wisc.edu/alexander-disease/
mutation-table.pdf) and the genotype-phenotype correlation is
still unclear. There are mutations that cause both infantile and
juvenile-onset forms and other mutations that cause all three
forms (1, 5, 6). Single GFAP mutations cause heterogeneous
neurological symptoms that can vary in severity among members
of the same family (6). The progression rate also is variable,
with a case of self-remitting AxD described in the literature
(7). This heterogeneity suggests that still unknown genetic
or environmental factors probably modify age at onset or
progression of disease. Describing new cases is therefore
important. Here we describe the onset and progression of
neurological symptoms in an adult patient bearing a new
mutation of the GFAP gene. We also demonstrate in vitro that
this novel mutation affects the formation of the intermediate
filament (IF) network.
MATERIALS AND METHODS
Clinical Assessment and Brain Imaging
The study was approved by the Ethics Committee of the IRCCS
Istituto Auxologico Italiano. Written, informed consent for this
study and for publication of this case report was obtained from
the patient. The patient underwent 3T brainMRI (Siemens Scan).
Lung function was assessed using a non-contact non-invasive
system (Thora-3DITM, PneumaCare Limited) with the patient in
supine position at rest.
Genetic Analysis
DNA was extracted from peripheral blood. The nine exons,
and corresponding exon–intron boundaries of the GFAP
gene, isoform 1 (RefSeq NM_002055.5) were amplified and
sequenced as described previously (8). The polymerase chain
reaction (PCR) amplification reactions were performed on
ABI 9700 and/or ABI 2700 thermal cyclers. The following
primers were used for PCR amplification: exon1FOR ctccttcataa
agccctcgc, exon1REV gatagtgccccatcaagagg, exon2-3FOR aggca
ggtattcaagtgtcc, exon2-3REV atttggtgtctctacctgcc, exon4FOR
caagagagcattcgaactcc, exon4REV aggatattctcccagcttcc, exon5-
6FOR gtgttgtgctaggtgctgagg, exon5-6REV gtgactgcctgctatgtgt
gagg, exon7FOR gctaggagatggagttagac, exon7REV aagtaccct
ggtatgataggc, exon8FOR ctgctcggttgcataggttc, exon8REV gctgg
gaaccttctatgtgc, exon9FOR tcctaactgttgcactgtgc, exon9REV gagc
aactatcctgcttctg. Temperature profiles for all PCR amplifications
were: initial 5min denaturation at 95◦C, followed by 30 cycles
at 96◦C for 30 s, 55◦C for 20 s, 72◦C for 45 s, and a final
5min extension at 72◦C. All reaction conditions were optimized
to obtain substantial uniformity of annealing temperature
(55◦C) and Mg2+ concentration (1.5mM). Subsequently, 10
µl of the PCR products were separated and purified from
single-stranded DNA chains and non-linked oligonucleotides
by enzymatic digestion with exonuclease I and shrimp alkaline
phosphatase combined in an Exo-SapIT kit (USB-Amersham).
Purified PCR products were then directly sequenced using the
BigDyeTM Terminator v3.1 Cycle Sequencing Kit (ThermoFisher
Scientific) and run on an ABI PRISM 3100 Genetic Analyzer
(ThermoFisher Scientific).
Cellular Assay
Plasmid encoding human GFAP was purchased from OriGene
Technologies (SC118873). The point mutations M73I and R239C
were introduced (QuikChange XL Site-Directed Mutagenesis
Kit, Agilent) and verified by Sanger sequencing. HeLa cells
were grown in Dulbecco’s modified Eagle’s medium, 10% fetal
bovine serum, 1% Pen-Strep, 5% CO2 at 37
◦C, and transfected
using lipofectamine 2000; 48 h after transfection the cells
were immunostained with mAb #3670 Cell signaling GFAP
(1: 300). Fluorescence images were acquired using a confocal
microscope (Leica TCS). Image acquisition and morphometric
quantification were performed by investigators blinded to the
experimental condition.
CASE PRESENTATION
Clinical Reports
A Caucasian woman, born in 1960, was diagnosed with
ovarian cancer (pT3cN1G3) in 2008 and treated with surgery,
carboplatin, and paclitaxel. During the second and third
chemotherapy cycles (seven cycles in total), her relatives noted
onset of an imperfect utterance of words and an unstable and
wide-base gait. Since the patient initially thought her symptoms
were adverse effects of the chemotherapy, she did not ask for
neurological evaluation. In 2009 her neurological symptoms
suddenly worsened. Neurological assessment carried out at the
emergency department disclosed asymmetric spasticity, with
mild left-limb weakness, dysarthria, and ataxia. Computed
tomography (CT) scan of the brain revealed no acute ischemic
damage or hemorrhage. The patient refused further clinical
investigations. A few months later, she developed diaphragmatic
metastasis and underwent surgery followed by hyperthermic
intraperitoneal chemotherapy with cisplatin and mitomycin C.
Since her neurological symptoms remained generally unchanged,
neurological investigations were delayed further.
On admission to our hospital in 2014, neurological
examination revealed slurred speech, mild dysphagia,
spastic tetraparesis involving mainly the left side, increased
muscle stretch reflexes and Babinski sign, bilateral horizontal
nystagmus, dysmetria, ataxia, and moderate dysdiadochokinesia.
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Cognitive testing was normal. Review of the family history
disclosed that her father had a gait disturbance, diagnosed
as a possible post-polio syndrome, and her 56-year-old sister
had a gait disturbance, as well. No further family information
was available. Hematologic screening and cerebrospinal fluid
(CSF) examination were normal. No paraneoplastic antibodies
(anti-Yo, -Hu -Ri) were detected in serum or CSF. Cerebral and
spinal MRI showed marked atrophy from the medulla oblongata
to the upper cervical spinal cord with dorsal enhancement. The
pons was slightly atrophic, with a peculiar tadpole-like atrophy
of the brainstem. Periventricular hyperintensity was observed on
fluid attenuation inversion recovery (FLAIR) MRI (Figure 1).
Overall, the clinical and radiological features were suggestive of
AxD. Genetic analysis disclosed a novel missense mutation in
the GFAP gene (see Genetic Findings).
The neurological examination performed in 2018 showed
the onset of weakness in the sternocleidomastoid, trapezius,
and proximal upper limb muscles. Because of severe worsening
of lower limb spasticity, the patient used a wheelchair.
The neurological examination also showed the onset of a
palatine tremor (at ≈2Hz) and square waves jerks. A formal
neuropsychological evaluation disclosed selective impairment
of executive and attentional abilities, together with mild
involvement of verbal memory, while the other cognitive
functions and global cognition were preserved (Mini Mental
State Examination raw score 28/30). Impulsivity was noted
during cognitive testing. A formal assessment of behavior
(Frontal Behavioral Inventory, FBI) revealed the presence of
prevailing negative symptoms (apathy, aspontaneity, inflexibility,
and personal neglect) accompanied by irritability (FBI total score
15/72, Negative Behaviors total score 9/36; Disinhibition total
score 6/36). Some behavioral features were probably related to
the presence of moderate depressive symptoms, as confirmed
by the Beck Depression Inventory (BDI total score 27/63). No
neurological therapy was administered.
Starting in 2016, the patient developed progressive cough
and bronchial asthma in relation to a history of smoking. In
January 2019 she was admitted to a respiratory day hospital
for acute bronchitis with respiratory failure (arterial blood
gases pH 7.36, pCO2 57.0mm Hg, pO2 54.5mm Hg, B.E. 11
FIGURE 1 | Axial and coronal FLAIR MRI show signal hyperintensity prevalent in the cerebral posterior periventricular regions (arrows in A,B) and in the hilum of the
dentate nuclei (arrow in C). Midbrain and pons show peripheral rim of hyperintensity (arrow in D). Axial T2-weighted sections show increased signal intensity in the
hilum of the dentate nuclei (arrow in E). A sagittal T2-weighted image shows atrophy and signal change in the medulla and spinal cord, “tadpole sign” (arrow in F).
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FIGURE 2 | (A) The GFAP exon 1 sequence, obtained from a control (top) and
our patient (bottom). The bottom picture shows heterozygosity for the
missense c.219G>C nucleotide change, corresponding to the p.M73I
mutation. (B) Representative images showing HeLa cells transiently
transfected with plasmids encoding human wild-type GFAP or mutant GFAP
M73I and R239C and labeled with GFAP antibody. The image shows wild-type
GFAP assembled in filament networks, whereas mutant M73I and R239C
formed dot-like aggregates. On the right, a detail is given of the Sanger
sequences of the plasmids encoding wild-type GFAP and GFAP M73I; codon
73 was mutated from ATG (Met) to ATC (Ile).
mmol/L, HCO3 38.6 mmol/L, SO2 84%). Chest X-ray showed
no major alterations. The respiratory pattern during bronchial
exacerbation was recorded with the patient in supine position
at rest (PneumaCare Thora-3DITM). Paradoxical respiration is
shown in Supplementary Figure 1. Non-invasive ventilation led
to an improvement in respiratory symptoms.
Genetic Findings
Genetic analysis of the GFAP gene detected a heterozygous
mutation in exon 1 (c.219G>C), resulting in an amino acid
exchange at codon 73 from methionine to isoleucine (p.M73I)
(Figure 2A). Consistent with highly conserved Met73 (GERP++
= 2.26), the present substitution to an isoleucine residue was
not found in 125,748 GnomAD exomes and 15,708 GnomAD
genomes (https://gnomad.broadinstitute.org/). Three different
missense mutations at the same residue of the GFAP protein
have been previously reported: p.M73R, p.M73K, and p.M73T.
These missense variants are all classified as “likely pathogenic”
and, indeed, found only in association with AxD (5, 8, 9) but
not in 125,748 GnomAD exomes and 15,708 GnomAD genomes.
Coherent with the role the present GFAP mutation can play,
several in silico analyses have predicted the p.M73I substitution to
be pathogenic (https://varsome.com/). Since parental screening
could not be performed, an either “de novo” or inherited nature
of the p.M73I mutation remains to be defined.
In vitro Model
GFAP is a key IF protein responsible for the assembly of
the cytoskeleton in glia cells. Previous papers showed that
AxD-associated mutations perturb IF assembly (1). To test
whether this new mutation p.M73I affects IF network formation,
we transfected HeLa cells with plasmids that encode human
wild-type or mutated GFAP, including the p.M73I, and the
previously described AxD mutation p.R239C (https://www2.
waisman.wisc.edu/alexander-disease/mutation-table.pdf). Wild-
type GFAP assembled into bundled filaments that extended
throughout the cytoplasm; the proportion of cells showing GFAP
aggregates from the transfected wild-type-GFAP was 0.00%. Both
M73I-GFAP and R239C-GFAP failed to assemble into filaments;
instead, they formed clusters of cytoplasmic aggregates. The
proportion of cells transfected with M73I-GFAP and R239C-
GFAP showing GFAP aggregates was 100% (n = 170 HeLa
cells transfected with wild-type-GFAP, n = 148 cells transfected
with M73I-GFAP, n = 172 cells transfected with R239C-GFAP,
Chi-square 490.0, df 2, p < 0.0001, Figure 2B).
DISCUSSION
We have identified a new GFAP mutation in a patient with
an adult form of AxD. This mutation causes the substitution
of the amino acid methionine at codon 73 with an isoleucine
(p.M73I). Three different missense mutations at the same residue
of the GFAP protein have been reported: p.M73R, p.M73K, and
p.M73T. p.M73R was found in a juvenile case of AxD: a boy with
disease onset at 9 years of age, affected by dysphagia, frequent
episodes of vomiting and choking, dysarthria, slurred speech, and
strabismus (9). p.M73K was found in an infantile type of AxD:
a male infant with severe symptoms and onset at 7 months of
age (8). p.M73T was described in three severe cases of infantile
AxD: a male with onset at 3 months of age that presented with
seizures and died at 2 years of age (5); a neonate (10) and, in cis
with another missense GFAP variant, p.V87F, in another case of
infantile AxD (11).
We wondered why the p.M73I mutation is associated with
a less severe form and adulthood onset. A hydrophobic side
chain characterizes methionine. The amino acid changes from
Met73 to either Arg or Lys introduce a positive charge, whereas
p.M73T introduces a polar amino acid. These charge-altering
substitutions may alter the oligomerization or solubility of the
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GFAP protein. Conversely, because it bears a hydrophobic side
chain, isoleucine resembles the methionine structure, leading to
few changes in the chemico-physical properties of codon position
73. We speculate that p.M73I leads to an adult form of AxD
because its effect on GFAP protein structure is milder than that
of mutations p.M73R/K/T.
The patient in the present case had adult onset with
typical AxD symptoms, such as dysarthria and ataxia. The
early symptoms started during chemotherapy, but a correlation
between the chemotherapy and the onset of neurological
symptoms is tenuous. A case report described clinical worsening
in an infantile form of AxD following cisplatin and vincristine
administered in the erroneous suspicion of an astrocytoma (12).
Since other studies suggested that environmental factors may
cause AxD onset or modify its course (1), we may speculate
that the proinflammatory state induced by cancer, in addition
to the cytotoxic effects of cancer therapy, may have triggered the
disease onset.
The appearance of palatal tremor and square-wave jerks in
our patient reflects the progressive damage to the brainstem
and cervical cord, a feature typical of AxD. We also noted
a potential effect of the palatal tremor on chest expansion
during inspiration (Supplementary Figure 1). Whether this
effect significantly interfered with breathing in our patient is
uncertain, given her history of bronchial asthma. The finding
of respiratory involvement in our patient is shared by the
observation of previous case reports that sleep apnoea and
respiratory dysfunction may appear during the progression of
adult onset AxD (13, 14). The cause of respiratory involvement in
AxD remains poorly understood: previous studies suggested that
epiglottic dysfunction causes obstructive sleep apnoea (14) and
that palatal and laryngeal tremor can interrupt laryngeal airflow
(13). A larger study investigating respiratory dysfunctions in AxD
is needed to clarify these aspects.
MR imaging criteria of AxD in a study of juvenile
AxD include extensive cerebral white matter changes with
frontal predominance, periventricular rim with high signal
on T1-weighted images and low signal on T2-weighted
images, abnormalities of basal ganglia and thalami, brain stem
abnormalities, and contrast enhancement of particular gray
and white matter structures (15). We observed no frontal
white matter abnormalities and periventricular involvement was
scarce in our patient. These findings agree with a previous
description of late-onset AxD in which atypical MRI features
were sparse involvement of the periventricular white matter,
predominance of posterior fossa white abnormalities, brainstem
atrophy, cerebellar atrophy, and spinal cord atrophy (3). In their
study of a cohort of 13 patients with late-onset AxD, Graff-
Radford et al. found white matter involvement in <50%; the
few with severe or moderate white matter involvement had a
younger age at onset than our patient (4). Hence, the MRI
alterations seen in our patient were milder than those previously
described and may reflect the later onset and slow progression
of the disease.
In conclusion, we describe the onset and progression of
neurological symptoms in an adult patient bearing a new
missense mutation of the GFAP gene. We also demonstrate
in vitro that this novel mutation affects the formation of the
intermediate filament network.
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